LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY

被引：0

作者：

Platzbecker, U. ^{[1
]}

Germing, U. ^{[2
]}

Giagounidis, A. ^{[3
]}

Goetze, K. ^{[4
]}

Kiewe, P. ^{[5
]}

Mayer, K. ^{[6
]}

Ottmann, O. ^{[7
]}

Radsak, M. ^{[8
]}

Wolff, T. ^{[9
]}

Haase, D. ^{[10
]}

Hankin, M. ^{[11
]}

Wilson, D. ^{[11
]}

Zhang, X. ^{[11
]}

Laadem, A. ^{[12
]}

Sherman, M. ^{[11
]}

Attie, K. ^{[11
]}

机构：

[1] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[2] Univ Klinikum Dusseldorf, Dusseldorf, Germany

[3] Marien Hosp, Dusseldorf, Germany

[4] Tech Univ Munich, D-80290 Munich, Germany

[5] Onkol Schwerpunkt Oskar Helene Heim, Berlin, Germany

[6] Univ Klinikum Bonn, Bonn, Germany

[7] Klinikum JW Goethe Univ Frankfurt, Frankfurt, Germany

[8] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55122 Mainz, Germany

[9] OncoRes Lerchenfeld UG, Hamburg, Germany

[10] Univ Med Gottingen, Gottingen, Germany

[11] Acceleron Pharma, Cambridge, MA USA

[12] Celgene Corp, Summit, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S509

引用

页码：192 / 192

页数：1